Diagnosing and managing growth failure in 45,X karyotype — from clinical suspicion through karyotype confirmation, Turner-specific growth curves, high-dose GH therapy, and lifelong surveillance
Turner syndrome (45,X and variants) affects roughly 1 in 2,000–2,500 live-born females, yet the average age at diagnosis without prenatal or neonatal detection still lags to 6–13 years — because the phenotype spans a wide spectrum from the classically affected newborn with dramatic lymphedema to the mildly mosaic teenager whose only clue is a height that quietly falls off the growth curve. Short stature is the single most consistent finding, present in more than 95% of affected girls, and is grounds on its own for karyotype testing.
Turner syndrome does not present as one fixed picture — it unfolds differently depending on when a clinician is looking:
Prenatal: cystic hygroma or nuchal translucency on obstetric ultrasound, fetal hydrops, left-sided cardiac anomalies on fetal echocardiography. Many 45,X conceptions are lost to first-trimester miscarriage; those that survive to term are enriched for milder mosaic karyotypes.
Neonatal: lymphedema of the hands and feet (puffy digits, deep-set nails) is often the presenting sign in the newborn nursery, along with redundant nuchal skin (webbed neck), low posterior hairline, low-set or posteriorly rotated ears, and a broad "shield" chest with widely spaced nipples.
Childhood: growth failure becomes the dominant and most persistent feature — a decelerating height velocity that crosses percentiles downward on standard growth curves, often without any other obvious dysmorphism, particularly in mosaic cases.
Adolescence: absent or arrested pubertal development (streak gonads, ovarian insufficiency), combined with a growth curve that never shows the expected pubertal spurt — the combination of short stature and pubertal delay is one of the most common referral triggers to pediatric endocrinology.
Short stature deserves emphasis because it is by far the most reliable and common finding, present even in girls with an otherwise unremarkable, non-dysmorphic appearance:
• Onset is prenatal — mean birth length is modestly reduced (~1 SD below average) • Postnatal growth deceleration begins in infancy and continues steadily through childhood • Growth failure occurs despite normal or even mildly elevated growth hormone secretion — this is the critical distinguishing feature from classic GH deficiency, and the reason growth hormone stimulation testing is not required before starting therapy • There is no pubertal growth spurt in the roughly 70–80% of girls with spontaneous ovarian failure, further compounding the height deficit • Untreated adult height averages 20 cm below the general population mean
Because growth failure can be the only sign, any girl whose height is persistently below the 2.5th percentile, or who is crossing growth percentiles downward without another explanation, should be considered for karyotype testing — regardless of whether any other Turner stigmata are present.
Short stature has many causes (familial short stature, constitutional delay, GH deficiency, chronic disease, skeletal dysplasia, SGA without catch-up growth), so Turner syndrome must be actively considered rather than assumed away:
• Any girl with unexplained short stature — even with no other findings — warrants karyotype testing as part of the standard short-stature work-up • Short stature plus any single classical stigma (webbed neck, cubitus valgus, shield chest, low hairline, history of neonatal lymphedema) substantially raises pretest probability • Congenital heart disease (especially left-sided lesions: bicuspid aortic valve, coarctation of the aorta) in a female infant should also prompt karyotype testing • Delayed or absent puberty by age 13 in a girl, particularly combined with short stature, is a strong indication
Because karyotype testing is inexpensive, minimally invasive, and definitive, the threshold for testing is intentionally kept low — missing the diagnosis delays growth-hormone initiation and surveillance for the syndrome's serious cardiac and renal comorbidities.
A clinical impression of Turner syndrome must always be confirmed cytogenetically. Peripheral blood karyotype remains the diagnostic gold standard, revealing whether a girl has classic 45,X monosomy, a mosaic 45,X/46,XX cell line, or a structural X abnormality such as an isochromosome Xq, ring X, or partial deletion. The specific karyotype — and especially the proportion of cells carrying a second, structurally normal X — is the single largest driver of how variable the clinical phenotype turns out to be.
Standard cytogenetic confirmation is performed on cultured peripheral blood lymphocytes using G-banding:
• A minimum of 20 metaphase spreads are counted for a routine karyotype; laboratories typically extend this to 30, and up to 50–100, when mosaicism is suspected or when the karyotype result does not match the clinical phenotype • Result is reported using International System for Human Cytogenomic Nomenclature (ISCN): e.g. 45,X (classic monosomy); 45,X/46,XX (mosaic); 46,X,i(Xq) (isochromosome of the long arm); 45,X/46,X,r(X) (ring X mosaic) • The more metaphases counted, the more sensitive the test is to low-level mosaicism — a karyotype counting only 20 cells can miss a second cell line present in fewer than 1 in 20 cells
Fluorescence in situ hybridization (FISH) complements the standard karyotype:
• Centromeric X and Y probes provide a rapid (24–48 hour) confirmation while the full karyotype culture (5–14 days) is pending • SRY / Y-specific FISH is essential in any girl with a marker chromosome, ambiguous genitalia, or virilization — occult Y-chromosome material occurs in roughly 5% of Turner syndrome cases and carries a 12–30% risk of gonadoblastoma arising in dysgenetic gonadal tissue • When blood karyotype is discordant with the clinical phenotype (e.g. classic 45,X result in a girl with spontaneous puberty, or a normal 46,XX result in a girl with a strongly suggestive phenotype), a second tissue — buccal smear or skin fibroblast karyotype — should be obtained, since mosaicism can be tissue-limited and undetectable in blood alone.
Because occult Y-chromosome material raises gonadoblastoma risk, any marker chromosome or ambiguous SRY/Y FISH result should trigger prophylactic gonadectomy discussion — this is one of the few time-sensitive surgical decisions in Turner syndrome management.
Mosaicism explains much of the striking variability seen from one Turner syndrome patient to the next:
• A higher proportion of a normal 46,XX cell line generally correlates with a milder phenotype: taller final height, greater likelihood of spontaneous puberty, and fewer somatic stigmata • Girls who are more heavily 45,X (low or no 46,XX mosaicism) tend to have the classic severe phenotype: more pronounced short stature, higher rates of cardiac and renal anomalies, and near-universal ovarian failure • Structural X abnormalities (isochromosome Xq, ring X, terminal deletions) produce intermediate and sometimes atypical phenotypes depending on which genes — including SHOX in the pseudoautosomal region — remain in two functional copies • This spectrum is why two girls with a "Turner syndrome" label can look clinically very different, and why the karyotype report, not the physical exam alone, should guide the specific surveillance and counseling plan.
Once the karyotype confirms Turner syndrome, growth must be tracked on Turner-specific growth charts rather than general population (CDC/WHO) curves. This matters because Turner syndrome short stature is not driven by classic growth hormone deficiency — it is driven predominantly by haploinsufficiency of the SHOX gene in the pseudoautosomal region of the X chromosome, producing a distinct, well-characterized growth trajectory that a standard population chart will systematically misjudge.
Plotting a Turner syndrome patient on a standard population growth curve creates two related problems:
• It delays recognition of the severity of growth failure, because the population curve does not reflect the syndrome's own natural history — a girl who looks like she is "just short" on a CDC chart may already be significantly growth-impaired relative to other girls with Turner syndrome • More importantly, it removes the clinician's ability to detect a second, superimposed problem. Once a patient is plotted on her OWN syndrome-specific curve, any additional deviation below that curve is a red flag for something beyond Turner syndrome itself — untreated hypothyroidism, celiac disease, true coexisting GH deficiency, or poor GH therapy adherence — each of which is common enough in Turner syndrome to actively screen for when growth trails the syndrome-specific expectation.
Turner-specific charts (originally published by Lyon et al. in 1985, and updated by Ranke and colleagues using larger modern cohorts) plot height, weight, and growth velocity against age using data collected specifically from girls with cytogenetically confirmed Turner syndrome not on growth-promoting therapy.
SHOX (Short stature HOmeoboX-containing gene) sits in the pseudoautosomal region 1 (PAR1) at the tip of the short arm of the X chromosome — a region present on both the X and Y chromosomes and therefore normally expressed from two active gene copies in both males and typical 46,XX females.
• In Turner syndrome, only one sex chromosome is present (or one is structurally abnormal), so only a single functional SHOX copy remains — haploinsufficiency • SHOX encodes a transcription factor essential for growth plate chondrocyte proliferation, particularly in the limbs; haploinsufficiency produces a recognizable skeletal dysplasia phenotype: disproportionate short stature, Madelung deformity of the wrist, high-arched palate, short fourth metacarpal, and cubitus valgus • This is mechanistically distinct from classic growth hormone deficiency — the GH/IGF-1 axis in Turner syndrome is typically intact or even mildly overactive, which is exactly why GH stimulation testing is not required before starting therapy, and why the therapeutic target is pharmacologic override of skeletal SHOX insufficiency rather than replacement of a missing hormone.
At every visit (typically every 3–6 months in childhood), the clinician should record and plot:
• Height (to the nearest 0.1 cm, ideally same equipment/technician for consistency) • Weight and BMI • Growth velocity (cm/year), which is often more sensitive than a single height point for catching deceleration early • Bone age (hand/wrist X-ray), obtained periodically to assess skeletal maturation relative to chronological age and to help refine predicted adult height, especially once GH or oxandrolone therapy begins
A growth velocity that falls below the patient's own percentile band on the Turner-specific curve — even if her absolute height still looks "fine" for a Turner syndrome patient — should prompt screening for thyroid dysfunction, celiac disease, poor treatment adherence, or a re-evaluation of GH dosing.
Growth hormone therapy is the cornerstone intervention for Turner syndrome short stature, but the dosing paradigm differs sharply from classic growth hormone deficiency. Because the problem is skeletal SHOX-related resistance rather than a missing hormone, Turner syndrome requires pharmacologic — often roughly double standard GHD — doses, started as early as age 2, to meaningfully change adult height outcomes.
In isolated growth hormone deficiency, therapy replaces a hormone that is genuinely insufficient, so relatively modest physiologic doses (commonly 0.17–0.24 mg/kg/week) restore normal growth. Turner syndrome is different:
• GH secretion in Turner syndrome is typically normal, and IGF-1 levels are often already within or above the normal range even before treatment • The rate-limiting problem is at the level of the SHOX-deficient growth plate itself, not hormone availability — the skeleton is relatively resistant to a "normal" GH signal • Overcoming this resistance requires supraphysiologic, pharmacologic dosing — up to 0.375 mg/kg/week, roughly double the ceiling used for classic GH deficiency — to drive a clinically meaningful increase in growth velocity and, ultimately, adult height • Because the underlying problem is not a deficiency state, formal GH stimulation testing is not required before starting therapy in a girl with confirmed Turner syndrome and documented growth failure — a key practical difference from the GHD work-up pathway.
Timing strongly influences the eventual benefit:
• Therapy should begin as soon as growth failure is documented — height falling below roughly the 5th percentile for age, or a downward-crossing growth curve on the Turner-specific chart — which can be as young as age 2 • Starting earlier extends the total number of prepubertal treatment-years, which is strongly associated with greater cumulative adult height gain, since the prepubertal growth plates remain responsive for longer before pubertal induction (with estrogen) begins to advance bone age and close the plates • Dosing is titrated using growth velocity response and IGF-1 monitoring: the goal is to keep IGF-1 within, or only modestly above, the age- and sex-adjusted normal range (generally targeting below +2 SDS) to balance growth benefit against theoretical long-term risks of chronically elevated IGF-1 • Regular monitoring includes height/growth velocity every 3–6 months, annual bone age, and periodic IGF-1 levels, with dose adjustments as weight changes through childhood.
Two additional decisions shape final adult height outcomes:
• Oxandrolone, a weak non-aromatizable anabolic steroid, may be added around age 9–10 in girls with a particularly poor predicted adult height on GH monotherapy. Low doses (roughly 0.03–0.05 mg/kg/day) are used to minimize virilizing side effects (voice deepening, clitoromegaly) and excessive bone-age advancement, both of which are monitored closely during co-therapy.
• Estrogen replacement for pubertal induction must be carefully sequenced with growth-promoting therapy: starting estrogen too early accelerates epiphyseal (growth plate) fusion and can blunt the very height gains GH and oxandrolone are working to achieve. Pubertal induction is therefore typically delayed until roughly age 11–12, using an ultra-low-dose transdermal estradiol regimen that is gradually increased over 2–3 years to mimic normal puberty — balancing psychosocial benefits of timely puberty against preserving growth potential.
Growth failure is only one piece of Turner syndrome; the karyotype abnormality affects nearly every organ system, and several of the associated risks — most critically aortic dissection — are life-threatening if unrecognized. Comprehensive, lifelong, multidisciplinary surveillance is therefore as essential to Turner syndrome care as growth hormone therapy itself, spanning cardiology, nephrology, endocrinology, gynecology, audiology, and psychology.
Congenital and acquired cardiovascular disease is the leading cause of excess mortality in Turner syndrome, so cardiac surveillance is treated as non-negotiable:
• Baseline echocardiogram and cardiac MRI at diagnosis to screen for bicuspid aortic valve, coarctation of the aorta, partial anomalous pulmonary venous return, and to obtain baseline aortic dimensions • Aortic Size Index (ASI) — aortic root diameter indexed to body surface area — is tracked longitudinally, since Turner syndrome carries an elevated, syndrome-specific risk of progressive aortic root dilation and dissection, independent of a bicuspid valve • Blood pressure is measured at every clinical encounter; hypertension is common in Turner syndrome and compounds aortic wall stress • Imaging is repeated periodically (typically every 5–10 years in low-risk patients, more frequently if risk factors such as bicuspid valve, coarctation, or hypertension are present, and around pregnancy given markedly elevated dissection risk during gestation).
Aortic dissection is a leading cause of premature death in Turner syndrome and can occur even in the absence of a known bicuspid valve or coarctation — ASI monitoring is what allows clinicians to intervene before catastrophic dissection occurs.
Beyond the heart, several other systems require structured, scheduled screening:
• Renal ultrasound at diagnosis to identify structural anomalies — horseshoe kidney (~10%), duplicated collecting system, or unilateral renal agenesis — which can predispose to hypertension and urinary tract infection • Annual TSH and anti-thyroid peroxidase (anti-TPO) antibody screening, since autoimmune (Hashimoto) hypothyroidism affects roughly a quarter to a third of women with Turner syndrome over their lifetime • Celiac disease screening (tissue transglutaminase antibodies), given an increased prevalence compared with the general population • Glucose and lipid monitoring — Turner syndrome carries increased lifetime risk of type 2 diabetes, dyslipidemia, and metabolic syndrome • Hearing evaluation — recurrent otitis media in childhood and progressive sensorineural hearing loss in adulthood are both more common and are screened with periodic audiometry.
The majority of girls with Turner syndrome — roughly 70–90% — experience premature ovarian insufficiency and require exogenous estrogen to induce and maintain puberty:
• Pubertal induction typically begins around age 11–12 with ultra-low-dose transdermal estradiol, chosen over oral estrogen to more closely mimic physiologic estradiol exposure and to minimize the growth-plate-advancing first-pass hepatic effects of oral therapy • The dose is increased gradually over 2–3 years to replicate the tempo of normal puberty; cyclic progesterone is typically added once breakthrough bleeding occurs or after roughly two years of estrogen therapy, to protect the endometrium • Fertility counseling is an essential, sometimes underemphasized component: spontaneous pregnancy is possible only in the minority of girls with substantial 46,XX mosaicism, so oocyte or ovarian tissue cryopreservation should be discussed proactively, ideally before ovarian reserve is exhausted • Because Turner syndrome touches endocrine, cardiac, renal, auditory, reproductive, and psychosocial domains simultaneously, durable outcomes depend on a coordinated multidisciplinary team — pediatric and adult endocrinology, cardiology, gynecology, genetics, ENT, and psychology — with a deliberate, structured transition plan from pediatric to adult care in the late teens.